- SQI Diagnostics (SQD) reported its financial and operational results for the second quarter of fiscal 2022
- Highlights include record sales of $5.6M in Q2 2022, compared to $0.3M in Q2 2021
- Gross profit was $3.0M in Q2 2022, compared to $0.3M in Q2 2021
- SQI CEO Andrew Morris sat down with Coreena Robertson to discuss the results
- SQI Diagnostics Inc is a Canada-based company engaged in developing and commercializing technologies & products for multiplexing diagnostics
- SQI Diagnostics opened trading at C$0.17
SQI Diagnostics (SQD) reported its financial and operational results for the first quarter of the fiscal year ending September 30, 2022.
Financial highlights include record sales of $5.6M for Q2 and gross profit of $3.0M.
SQI Diagnostics CEO Andrew Morris sat down with Coreena Robertson to discuss the news.
“We’re extremely pleased with our revenue growth this quarter, which we see as a validation of our decision to grow our business through acquisition and new product lines.
As we move forward, we hope to see continued growth fueled by our core lung health products like our RALI-Dx™ IL-6 Severity Triage Test, Exact COVID19 Antibody test and our TOR-Dx Lung products.”
SQI Diagnostics is a Canada-based company engaged in developing and commercializing technologies & products for multiplexing diagnostics.
SQI Diagnostics Inc. (SQD) opened trading at C$0.17.
